Shares of GSK PLC GSK inched down 0.51% to £13.57 Friday, on what proved to be an all-around poor trading session for the ...

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Shares of GSK PLC GSK inched up 0.59% to £13.64 Thursday, on what proved to be an all-around positive trading session for the ...

Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

During Lacalle's meeting with British Prime Minister Boris Johnson, the launch of a sovereign bond linked to sustainability goals was discussed Pharmaceutical giant GlaxoSmithKline (GSK ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.